Cannabix Technologies Strengthens Presence in Maritime Market with Repeat BreathLogix Alcohol Screening Device Order

Rhea-AI Summary

Cannabix Technologies (OTCID: BLOZF) announced a second sales agreement to deliver an additional BreathLogix unmanned alcohol screening unit to an existing European maritime customer on Dec 2, 2025.

The device will integrate with the cloud-based BreathLogix Connect platform (powered by Amazon Web Services) for real-time alerts, centralized data management and reporting, and will include facial recognition for crew identification. BreathLogix supports multiple workplace testing scenarios and is listed on the U.S. Federal Register Conforming Products List (NHTSA). The system uses a patent-pending pre-calibrated sensor cartridge to reduce maintenance needs.

Positive

• Repeat commercial order from a European maritime customer
• AWS-backed cloud integration via BreathLogix Connect for real-time alerts
• NHTSA Conforming Products List listing for BreathLogix
• Patent-pending pre-calibrated sensor to reduce calibration visits

Negative

• No sales figures disclosed for the repeat order
• Regulatory and certification uncertainty noted in forward-looking caution
• Company statement that it is not currently selling breathalyzers and may not in future

News Market Reaction

-3.95%

1 alert

-3.95% News Effect

On the day this news was published, BLOZF declined 3.95%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $0.4187 Vol: Volume 89,856 vs 20-day a...

normal vol

$0.4187 Last Close

Volume Volume 89,856 vs 20-day average 109,033 (relative volume 0.82). normal

Technical Price at 0.356 is trading below the 200-day MA of 0.41.

Peers on Argus

Peers in Medical Devices showed mixed to negative moves, with names like ACIXF d...

Peers in Medical Devices showed mixed to negative moves, with names like ACIXF down -18.39% and RDGL down -8.45%, while POSC was flat. With BLOZF unchanged pre-news, this setup pointed more to stock‑specific catalysts than a broad sector move.

Historical Context

5 past events · Latest: Dec 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 09	Regulatory milestone	Positive	-0.0%	BCU device passed FCC and Canadian emissions testing for MBT system.
Dec 02	Commercial order	Positive	-4.0%	Second BreathLogix unit sale to existing European maritime customer.
Oct 27	Patent grant	Positive	+0.9%	USPTO granted patent for contact-free breath analysis device and method.
Oct 16	Commercial deployment	Positive	+2.6%	Delivered BreathLogix device to oil and gas transportation company.
Sep 30	First maritime sale	Positive	+16.8%	Announced first BreathLogix sale to European maritime customer.

Pattern Detected

Recent positive operational and regulatory updates have more often led to aligned price gains, but two latest news items saw slight to moderate negative reactions.

Recent Company History

This announcement continues a series of commercial and regulatory milestones for Cannabix. On Sep 30, the company reported its first BreathLogix sale to a European maritime customer, with a 16.78% price move. Subsequent news included an oilfield transportation deployment and a C$100,000 marketing agreement on Oct 16, and a USPTO patent grant for contactless breath analysis on Oct 27. A regulatory milestone for the Marijuana Breath Test BCU followed on Dec 09. The current repeat maritime order builds on this commercialization trajectory.

Market Pulse Summary

This announcement highlights a second BreathLogix alcohol screening unit order from an existing Euro...

Analysis

This announcement highlights a second BreathLogix alcohol screening unit order from an existing European maritime customer, reinforcing early traction in safety‑critical transportation settings. It builds on prior milestones, including the first maritime sale and deployments in oil and gas, as well as a recently granted U.S. patent for contact‑free breath analysis. Investors may watch how repeat orders develop across maritime and other industries and monitor additional regulatory clearances or patent progress as Cannabix advances its breath detection platforms.

Key Terms

blood alcohol content, facial recognition, conforming products list, nhtsa, +1 more

5 terms

blood alcohol content medical

"The system delivers precise Blood Alcohol Content (BAC or BrAC) readings on-screen"

Blood alcohol content (BAC) is the measure of the amount of alcohol present in a person’s bloodstream, expressed as a percentage that shows how saturated the blood is with alcohol—think of it like the concentration reading on a fuel gauge. It matters to investors because elevated BAC among executives, employees, or contractors can signal legal risk, safety incidents, regulatory fines, higher insurance costs, and reputational damage that may affect a company’s operations and financial performance.

facial recognition technical

"device will feature facial recognition technology for rapid and secure crew member identification"

Facial recognition is a technology that detects and compares human faces in images or video to identify or verify a person, like using a digital fingerprint for your face. Investors care because it can create new revenue streams across security, retail, and devices while also bringing costs and risks from privacy rules, legal challenges, and public pushback; its adoption and regulation can significantly affect a company’s growth and reputation.

conforming products list regulatory

"Workplace Series) is listed on the U.S. Federal Register Conforming Products List (CPL)"

A conforming products list is an official roster of items that a regulator or payer has reviewed and approved as meeting required safety, quality and usage standards, and therefore eligible for sale, reimbursement or formal use. For investors, inclusion is like getting a product stocked on a major retailer’s approved shelf: it often clears a key barrier to revenue, speeds market access, reduces regulatory risk and can boost competitive position and predictable cash flow.

nhtsa regulatory

"Conforming Products List (CPL) for breath alcohol screening devices, administered by the National Highway Traffic Safety Administration (NHTSA)"

NHTSA is the U.S. federal agency that sets and enforces safety rules for motor vehicles and conducts crash and defect investigations. Think of it as the country’s vehicle safety inspector and recall manager; its findings or orders can force repairs, halt sales, or trigger expensive recalls. Investors watch NHTSA actions because they can create unexpected costs, legal exposure, production delays, or shifts in consumer confidence that affect a company’s financial outlook.

forward-looking statements regulatory

"Cautionary Statement Regarding Forward-Looking Statements This news release contains certain "forward-looking statements""

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

AI-generated analysis. Not financial advice.

VANCOUVER, British Columbia, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company or Cannabix”) developer of marijuana and alcohol breath devices is pleased to announce that it has entered into a second sales agreement for its BreathLogix unmanned alcohol screening technology with an existing European maritime shipping customer. Under this agreement, the Company will deliver an additional BreathLogix unit to enhance operational safety among crew members through pre-access breath alcohol testing. The BreathLogix system will be integrated with the cloud-based BreathLogix Connect platform, powered by Amazon Web Services, enabling real-time alerts, centralized data management, and seamless reporting. Additionally, the device will feature facial recognition technology for rapid and secure crew member identification.

BreathLogix alcohol screening solutions are designed for deployment across multiple industries—including maritime, mining, oil and gas, industrial, trucking, and warehousing—where operational safety is critical.

Figure 1. BreathLogix Alcohol device available with contactless and straw modes for rapid workplace pre-access
alcohol screening

BreathLogix unmanned alcohol screening devices provide rapid and accurate breath alcohol checks while simultaneously capturing a photo of the user to confirm and record identity (Figures 1 and 2). The system delivers precise Blood Alcohol Content (BAC or BrAC) readings on-screen and sends real-time test reports via SMS and email, alerting managers to positive results so they can take immediate action to prevent accidents and injuries. All test results are securely logged and managed through the dedicated BreathLogix Connect web portal. The device can integrate with doors, turnstiles, gates, facial recognition systems, fingerprint readers, and motor vehicle key fleet management systems for pre-access alcohol testing. It supports multiple testing scenarios, including start-of-shift, mandated, pre-employment, return-to-work, random, and post-incident testing.

BreathLogix (Workplace Series) is listed on the U.S. Federal Register Conforming Products List (CPL) for breath alcohol screening devices, administered by the National Highway Traffic Safety Administration (NHTSA).

BreathLogix includes patent pending pre-calibrated sensor cartridge technology allowing administrators to easily maintain their devices and eliminate the need for costly calibration equipment and time-consuming site visits from technicians for maintenance.

Figure 2. BreathLogix Alcohol Screening Devices by Cannabix Technologies Inc.

We seek Safe Harbor.

On behalf of the Board of Directors

“Rav Mlait”

CEO
Cannabix Technologies Inc.

For further information, contact the Company at info@cannabixtechnologies.com

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates," "plan," "continue," "expect," "project," "intend," "believe," "anticipate," "estimate," "may," "will," "potential," "proposed," "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements in this news release include, but are not limited to, statements relating to: certification of devices, acceptance of devices by international regulators, the achievement of any or all of the goals and aims of the distribution and sales agreement with any third-party companies; positive developments with contract manufacturers; the completion of pre-validation or validation testing; final development of a commercial or prototype product(s); the successful trial or pilot of company technologies; the commercialization of the Company's products; the negotiation and potential entry into additional agreements with distributors and or contract manufacturers; and the completion of future financings. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. Important factors that could cause actual results to differ materially from those expressed in the forward-looking information include (but are note limited to): adverse market conditions; risks regarding protection of proprietary technology; the ability of the Company to complete future financings; the ability of the Company to develop and market its future product; risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition; that the Company’s development of cannabis and alcohol breathalyzer technologies will provide any benefit to the Company; there is no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials; there is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies; there is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities; the Company is not currently selling breathalyzers and there is no assurance that the Company ever will; and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.

Photos to accompanying this announcement are available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/eacfde8c-250e-4d63-abf1-c1f700e10ffb

https://www.globenewswire.com/NewsRoom/AttachmentNg/7566a746-454a-4802-a347-07408a535520

 

FAQ

What did Cannabix Technologies (BLOZF) announce on December 2, 2025 regarding BreathLogix?

Cannabix announced a second sales agreement to deliver an additional BreathLogix unmanned alcohol screening unit to an existing European maritime customer.

How will the delivered BreathLogix unit connect and report results for BLOZF customers?

The unit will integrate with BreathLogix Connect (powered by Amazon Web Services) for real-time alerts, centralized data management, and SMS/email reporting.

Does the BreathLogix device include biometric features in the BLOZF announcement?

Yes. The device will feature facial recognition to confirm and record crew member identity during testing.

Is BreathLogix listed on any U.S. federal equipment list per the BLOZF release?

Yes. BreathLogix (Workplace Series) is listed on the U.S. Federal Register Conforming Products List (NHTSA) for breath alcohol screening devices.

What maintenance advantage does BreathLogix claim in the BLOZF release?

BreathLogix uses a patent-pending pre-calibrated sensor cartridge intended to eliminate costly calibration equipment and reduce technician site visits.

What investor risks did Cannabix (BLOZF) warn about in the announcement?

The company cautioned about regulatory acceptance, certification uncertainty and stated it is not currently selling breathalyzers, with no assurance it will in future.